INO-4500

DRUG2 trials

Sponsors

Inovio Pharmaceuticals

Conditions

Lassa Fever

Phase 1

Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers

CompletedNCT03805984

Inovio PharmaceuticalsLassa Fever

Start: 2019-05-09End: 2020-10-21Updated: 2020-11-23

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana

CompletedNCT04093076

Inovio PharmaceuticalsLassa Fever

Start: 2021-01-27End: 2022-10-14Updated: 2022-11-21

Related Papers

Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults.

2025-10-24